Pembrolizumab and atezolizumab were approved in 2017 and are currently recommended by The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer (v3.2023) (6) as monotherapies specifically in the setting of 1L cisplatin-ineligible (atezolizumab only for patients whose tumors express PD-L1) or platinum-ineligible patients (pembrolizumab and atezolizumab irrespective of PD-L1 status). This evidence concerns the gene CD274 and urinary bladder carcinoma.